BRPI0715660B8 - anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal - Google Patents

anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal

Info

Publication number
BRPI0715660B8
BRPI0715660B8 BRPI0715660A BRPI0715660A BRPI0715660B8 BR PI0715660 B8 BRPI0715660 B8 BR PI0715660B8 BR PI0715660 A BRPI0715660 A BR PI0715660A BR PI0715660 A BRPI0715660 A BR PI0715660A BR PI0715660 B8 BRPI0715660 B8 BR PI0715660B8
Authority
BR
Brazil
Prior art keywords
antibody
polypeptides
human
binding
compositions
Prior art date
Application number
BRPI0715660A
Other languages
English (en)
Inventor
W Siadak Anthony
Bilsborough Janine
Rene Shirley
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0715660A2 publication Critical patent/BRPI0715660A2/pt
Publication of BRPI0715660B1 publication Critical patent/BRPI0715660B1/pt
Publication of BRPI0715660B8 publication Critical patent/BRPI0715660B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpo monoclonal ou fragmento de anticorpo, métodos para reduzir, bloquear, inibir, ou neutralizar inflamação, prurite e arranhadura em um mamífero, e, anticorpo isolado. são obtidas novas composições derivadas de sítios de ligação em antígeno de imunoglobulinas tendo afinidade por il-3 1. as composições exibem propriedades de ligação imunológicas de moléculas de anticorpo capazes de ligação especificamente em uma il-3 1 de humano. são obtidas regiões cdr derivadas de mesmos ou diferentes grupos de imunoglobulinas. também são obtidos polipeptídeos de cadeia única nos quais os domínios vh e vl estão ligados. as moléculas sfv podem incluir grupos de polipeptideo ancilares que podem ser bioativos, ou que proporcionam um sítio de ligação para outros grupos úteis. as composições são úteis em ensaios de ligação específicos, esquemas de purificação por afinidade, seleção de toxina ou droga, imagem, e agentes terapêuticos imunológicos ou genéticos para doenças inflamatórias. a invenção deste modo proporciona polipeptideos novos, os dnas codificadores daqueles polipeptídeos, cassetes de expressão compreendendo aqueles dnas, e métodos de indução da produção dos polipeptídeos. a invenção adicionalmente proporciona as seqtiências de aminoácidos das regiões variáveis dos anticorpos monoclonais e o uso destes anticorpos monoclonais ou fragmentos de anticorpo juntamente com uma molécula igg4 fc de humano.
BRPI0715660A 2006-09-01 2007-09-04 anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal BRPI0715660B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82440306P 2006-09-01 2006-09-01
US60/824403 2006-09-01
US89079207P 2007-02-20 2007-02-20
US60/890792 2007-02-20
PCT/US2007/077555 WO2008028192A2 (en) 2006-09-01 2007-09-04 Variable region sequences of il-31 monoclonal antibodies and methods of use

Publications (3)

Publication Number Publication Date
BRPI0715660A2 BRPI0715660A2 (pt) 2013-07-02
BRPI0715660B1 BRPI0715660B1 (pt) 2018-06-19
BRPI0715660B8 true BRPI0715660B8 (pt) 2021-05-25

Family

ID=38752366

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715660A BRPI0715660B8 (pt) 2006-09-01 2007-09-04 anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal

Country Status (19)

Country Link
US (6) US8466262B2 (pt)
EP (3) EP2061811A2 (pt)
JP (3) JP2010502652A (pt)
KR (1) KR101501660B1 (pt)
CN (2) CN101522713A (pt)
AU (1) AU2007290145B2 (pt)
BR (1) BRPI0715660B8 (pt)
CA (1) CA2660175C (pt)
CY (1) CY1115939T1 (pt)
DK (1) DK2594586T3 (pt)
ES (2) ES2519375T3 (pt)
HK (1) HK1199047A1 (pt)
IL (1) IL196914A (pt)
MX (1) MX2009002242A (pt)
PL (1) PL2594586T3 (pt)
PT (1) PT2594586E (pt)
RU (1) RU2009111884A (pt)
SI (1) SI2594586T1 (pt)
WO (1) WO2008028192A2 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
US20060188500A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
WO2007133816A2 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
DK2594586T3 (en) * 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
US7799323B2 (en) 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN103965363B (zh) * 2013-02-06 2021-01-15 上海白泽生物科技有限公司 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
SI3456743T1 (sl) 2013-05-30 2022-01-31 Kiniksa Pharmaceuticals, Ltd. Proteini, ki vežejo antigen receptorja onkostatina M
JP6085746B2 (ja) * 2014-08-11 2017-03-01 学校法人北里研究所 抗トロンボポエチン抗体の検出における検出感度の向上方法、免疫性血小板減少症の検出方法及びキット
JP6302813B2 (ja) * 2014-09-30 2018-03-28 日立ジョンソンコントロールズ空調株式会社 スクロール圧縮機及びこれを用いた冷凍サイクル装置
KR20170134748A (ko) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
US11073670B2 (en) 2016-08-12 2021-07-27 Corning Optical Communications LLC Device and method for sealing multiport splitters
WO2018112407A1 (en) * 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US12271040B2 (en) 2017-06-28 2025-04-08 Corning Research & Development Corporation Fiber optic extender ports, assemblies and methods of making the same
US11300746B2 (en) 2017-06-28 2022-04-12 Corning Research & Development Corporation Fiber optic port module inserts, assemblies and methods of making the same
US11187859B2 (en) 2017-06-28 2021-11-30 Corning Research & Development Corporation Fiber optic connectors and methods of making the same
WO2019005196A1 (en) 2017-06-28 2019-01-03 Corning Research & Development Corporation COMPACT FIBER OPTIC CONNECTORS HAVING MULTIPLE CONNECTOR IMPRESSIONS, IN CONJUNCTION WITH CABLE ASSEMBLIES AND METHODS OF MAKING SAME
US10359577B2 (en) 2017-06-28 2019-07-23 Corning Research & Development Corporation Multiports and optical connectors with rotationally discrete locking and keying features
US11668890B2 (en) 2017-06-28 2023-06-06 Corning Research & Development Corporation Multiports and other devices having optical connection ports with securing features and methods of making the same
WO2019086694A1 (en) * 2017-11-06 2019-05-09 Geert Mudde Il31 antigen and vaccine
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
US10641967B1 (en) 2018-11-16 2020-05-05 Corning Research & Development Corporation Multiport assemblies including a modular adapter support array
EP3887883B1 (en) 2018-11-29 2023-11-08 Corning Research & Development Corporation Multiport having connection ports with rotating actuators
US10768382B2 (en) 2018-11-29 2020-09-08 Corning Research & Development Corporation Multiport assemblies including access apertures and a release tool
CN109528663A (zh) * 2018-12-20 2019-03-29 江西润泽药业有限公司 以ngr(no2)为靶向载体的抗癌药物冻干粉剂及其制备方法和应用
CA3125271C (en) 2018-12-28 2024-02-27 Corning Research & Development Corporation Multiport assemblies including mounting features or dust plugs
EP3958903A4 (en) * 2019-04-24 2023-08-02 Janssen Biotech, Inc. ANTIBODY FORMULATION
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
MX2021014427A (es) 2019-05-31 2022-03-04 Corning Res & Dev Corp Multipuertos y otros dispositivos que tienen puertos de conexion optica con accionadores deslizantes y metodos para elaborar los mismos.
US11294133B2 (en) 2019-07-31 2022-04-05 Corning Research & Development Corporation Fiber optic networks using multiports and cable assemblies with cable-to-connector orientation
CA3147809A1 (en) * 2019-08-29 2021-03-04 Shyr Jiann Li Anti-il31 antibodies for veterinary use
US11487073B2 (en) 2019-09-30 2022-11-01 Corning Research & Development Corporation Cable input devices having an integrated locking feature and assemblies using the cable input devices
EP3805827B1 (en) 2019-10-07 2025-07-30 Corning Research & Development Corporation Fiber optic terminals and fiber optic networks having variable ratio couplers
PL4045957T3 (pl) 2019-10-18 2024-04-29 Corning Research & Development Corporation Terminale mające optyczne porty połączeniowe z elementami mocującymi zapewniającymi stałe siły utrzymania
US11650388B2 (en) 2019-11-14 2023-05-16 Corning Research & Development Corporation Fiber optic networks having a self-supporting optical terminal and methods of installing the optical terminal
CN114728064B (zh) 2019-11-20 2025-05-06 中外制药株式会社 含抗体制剂
US11536921B2 (en) 2020-02-11 2022-12-27 Corning Research & Development Corporation Fiber optic terminals having one or more loopback assemblies
EP4172671B1 (en) 2020-06-29 2026-01-21 Corning Research & Development Corporation Terminals having a multi-fiber optical connection port that inhibits damage from single-fiber connectors
US20230391878A1 (en) 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
US11604320B2 (en) 2020-09-30 2023-03-14 Corning Research & Development Corporation Connector assemblies for telecommunication enclosures
CA3197081A1 (en) 2020-10-30 2022-05-05 Stephen Paul CAPPANNARI Fiber optic connectors having a weatherproofing collar
US11927810B2 (en) 2020-11-30 2024-03-12 Corning Research & Development Corporation Fiber optic adapter assemblies including a conversion housing and a release member
US11994722B2 (en) 2020-11-30 2024-05-28 Corning Research & Development Corporation Fiber optic adapter assemblies including an adapter housing and a locking housing
US11686913B2 (en) 2020-11-30 2023-06-27 Corning Research & Development Corporation Fiber optic cable assemblies and connector assemblies having a crimp ring and crimp body and methods of fabricating the same
US11880076B2 (en) 2020-11-30 2024-01-23 Corning Research & Development Corporation Fiber optic adapter assemblies including a conversion housing and a release housing
EP4019547A1 (en) * 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
EP4019546A1 (en) * 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-31
KR20230123993A (ko) * 2020-12-23 2023-08-24 누맙 세러퓨틱스 아게 Il-31에 결합하는 항체 가변 도메인
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
US11947167B2 (en) 2021-05-26 2024-04-02 Corning Research & Development Corporation Fiber optic terminals and tools and methods for adjusting a split ratio of a fiber optic terminal
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN115505575B (zh) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用
CN117589031B (zh) * 2024-01-19 2024-03-19 四川铁道职业学院 一种受电弓碳滑板磨损检测工具及其检测方法
WO2025226834A1 (en) 2024-04-23 2025-10-30 Attovia Therapeutics, Inc. Il31-binding polypeptides and uses thereof
WO2026055142A1 (en) 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13 and il31 bispecific polypeptides and uses thereof
WO2026058155A1 (en) * 2024-09-11 2026-03-19 Novartis Ag Antibodies targeting il-31

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
WO1989012631A1 (en) 1988-06-24 1989-12-28 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
ZA894792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
JPH0578243A (ja) * 1990-12-11 1993-03-30 Shiseido Co Ltd 鎮痒剤及び鎮痒組成物
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JPH08501085A (ja) 1992-08-26 1996-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗腫瘍剤としてのサイトカインｉｐ−１０の利用
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1323346B1 (en) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CA2412239C (en) 2000-06-26 2013-05-28 Zymogenetics, Inc. Cytokine receptor zcytor17
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US8911726B2 (en) * 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
CA2594502A1 (en) 2005-01-28 2006-08-03 Zymogenetics Inc. Homogeneous preparations of il-31
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
US20060188500A1 (en) 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) * 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
WO2007133816A2 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
DK2594586T3 (en) * 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31

Also Published As

Publication number Publication date
US9624296B2 (en) 2017-04-18
US9011858B2 (en) 2015-04-21
EP2759549A3 (en) 2014-08-27
BRPI0715660A2 (pt) 2013-07-02
BRPI0715660B1 (pt) 2018-06-19
ES2548714T3 (es) 2015-10-20
AU2007290145B2 (en) 2012-11-01
KR101501660B1 (ko) 2015-03-11
US9878038B2 (en) 2018-01-30
DK2594586T3 (en) 2014-11-17
EP2594586B1 (en) 2014-08-27
ES2519375T3 (es) 2014-11-06
EP2594586A1 (en) 2013-05-22
US20150183869A1 (en) 2015-07-02
CN101522713A (zh) 2009-09-02
CA2660175A1 (en) 2008-03-06
WO2008028192A3 (en) 2008-05-15
EP2759549B1 (en) 2015-08-19
JP2016106105A (ja) 2016-06-16
HK1199047A1 (en) 2015-06-19
MX2009002242A (es) 2009-03-13
JP2014122220A (ja) 2014-07-03
WO2008028192A2 (en) 2008-03-06
EP2759549A2 (en) 2014-07-30
IL196914A (en) 2014-12-31
US20130266562A1 (en) 2013-10-10
RU2009111884A (ru) 2010-10-10
JP6174481B2 (ja) 2017-08-02
AU2007290145A1 (en) 2008-03-06
CA2660175C (en) 2015-05-12
CY1115939T1 (el) 2017-01-25
IL196914A0 (en) 2011-08-01
US20100008909A1 (en) 2010-01-14
PT2594586E (pt) 2014-11-26
JP2010502652A (ja) 2010-01-28
US20170182160A1 (en) 2017-06-29
US8466262B2 (en) 2013-06-18
SI2594586T1 (sl) 2014-11-28
US10434173B2 (en) 2019-10-08
EP2061811A2 (en) 2009-05-27
KR20090113818A (ko) 2009-11-02
CN103044550A (zh) 2013-04-17
US20190374637A1 (en) 2019-12-12
PL2594586T3 (pl) 2015-02-27
US20190038743A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
Wu et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
JP6779252B2 (ja) ＩＬ−１βへの結合メンバー
US9908944B2 (en) Antibodies that bind urokinase plasminogen activator
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
Jensen et al. A two-pronged binding mechanism of IgG to the neonatal Fc receptor controls complex stability and IgG serum half-life
BRPI0809042A8 (pt) Proteína de ligação a cd154 isolada, seu uso, e composição
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
BRPI0819909B8 (pt) anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica
ES2608381T3 (es) Anticuerpos anti-BMP-6
RS59557B1 (sr) Tau antitela i njihova upotreba
HRP20210744T1 (hr) Anti-c-met protutijela i njihovi konjugati protutijelo lijek za učinkovitu inhibiciju tumora
US12233125B2 (en) Method for treating pulmonary hypertension with antibodies to human Resistin
RU2009120536A (ru) Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf)
CN105518025A (zh) 人抗IFN-α抗体
RU2007118670A (ru) Ангиопоэтин-2-специфические связывающие агенты
JP2007529196A5 (pt)
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
PE20250753A1 (es) Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
HRP20120975T1 (hr) Terapeutska upotreba anti-cs1 antitijela
US20110071277A1 (en) Resistin antagonists and their use
ES2559422T3 (es) Antagonistas de resistina y su uso
JP2016510870A (ja) 補体因子ｈ関連タンパク質１検出のための剤、キットおよび方法
TW202417478A (zh) 用於治療支氣管擴張的抗PcrV和Psl雙特異性藥物
ES2961565T3 (es) Estratificación del riesgo de pacientes con leucemia linfoblástica aguda de precursores B

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2844 DE 08-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.